# US Transcatheter Embolization and Occlusion Devices Market > US Transcatheter Embolization and Occlusion Devices Market Research Report: Size, Share, Trend Analysis By Device Type (Coils, Particles, Gels, Liquid Embolic Agents), By Applications (Uterine Artery Embolization, Tumor Embolization, Devascularization Procedures, Hemorrhage Control), By End Users (Hospitals, Ambulatory Surgical Centers, Specialized Clinics) and By Technique (Transcatheter Embolization, Surgical Embolization) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.78% - **2024:** $ 604.7 Million - **2025:** $ 651.75 Million - **2035:** $ 1,378.67 Million - **Key Players:** Medtronic (US), Boston Scientific (US), Terumo Corporation (JP), Abbott Laboratories (US), Johnson & Johnson (US), Cook Medical (US), B. Braun Melsungen AG (DE), Stryker Corporation (US), Cardinal Health (US) **Report ID:** MRFR/MED/16105-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-transcatheter-embolization-and-occlusion-devices-market-17633 --- ## Market Summary ## **US Transcatheter Embolization and Occlusion Devices Market Overview** As per MRFR analysis, the US Transcatheter Embolization and Occlusion Devices Market Size was estimated at 561.05 (USD Million) in 2023. The US Transcatheter Embolization and Occlusion Devices Market Industry is expected to grow from 614.95 (USD Million) in 2024 to 1,380.36 (USD Million) by 2035. The US Transcatheter Embolization and Occlusion Devices Market CAGR (growth rate) is expected to be around 7.627% during the forecast period (2025 - 2035). ### **Key US Transcatheter Embolization and Occlusion Devices Market Trends Highlighted** The US Transcatheter Embolization and Occlusion Devices Market is witnessing significant growth due to several key market drivers. Increasing incidences of vascular diseases, coupled with a rising aging population in the US, is driving demand for minimally invasive procedures. Healthcare providers are increasingly adopting transcatheter techniques as these procedures typically result in quicker recovery times and reduced hospital stays. Additionally, advancements in technology have led to the development of innovative devices that are more effective and user-friendly, which further supports market growth. Opportunities within the US market also point towards the potential for expansion. There is an increasing focus on research and development, with various institutions exploring new embolization materials and devices aimed at improving patient outcomes. Regulatory support from US health authorities encourages the introduction of new technologies. Furthermore, the rise of telemedicine and remote monitoring presents an avenue for healthcare professionals to engage with patients undergoing embolization procedures, allowing for better follow-up care, which can enhance patient satisfaction. Trends in recent times reflect a growing awareness and acceptance of transcatheter embolization as an effective treatment option among both physicians and patients in the US. A notable shift towards personalized medicine is influencing device manufacturers to create customized solutions for specific conditions. Additionally, hospitals and clinics are increasingly partnering with device manufacturers for training and support, ensuring better device utilization and patient management. As more healthcare institutions recognize the benefits of these technologies, the market is likely to continue on a growth trajectory, driven by these evolving trends and emerging opportunities. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Transcatheter Embolization and Occlusion Devices Market Drivers** ### **Rising Incidence of Cancer and Vascular Diseases** The US Transcatheter Embolization and Occlusion Devices Market Industry is experiencing significant growth due to the increasing incidence of cancer and vascular diseases. According to the American Cancer Society, an estimated 1.9 million new cancer cases are expected to be diagnosed in the United States in 2023. As the demand for less invasive treatment options grows, transcatheter embolization devices become more sought after for procedures like tumor embolization and treatment of vascular malformations. Furthermore, the Centers for Disease Control and Prevention reported that nearly 84 million adults in the US are living with cardiovascular diseases. This alarming trend drives healthcare providers to seek advanced embolization and occlusion solutions, allowing for better patient outcomes while minimizing recovery times. Notable organizations like Medtronic and Boston Scientific are actively investing in Research and Development to enhance their product offerings in this segment, thereby contributing to the expansion of the US Transcatheter Embolization and Occlusion Devices Market. ### **Technological Advancements in Medical Devices** Technological advancements in medical device manufacturing are a significant driver of the US Transcatheter Embolization and Occlusion Devices Market Industry. Innovations in catheter technology, materials, and imaging techniques have improved procedural efficacy and safety. The FDA has accelerated the approval process for new medical devices, evidenced by an increase in the number of approved devices in recent years. In 2022, over 1,000 devices were approved by the FDA for various applications, including embolization. Companies such as Stryker and Abbott Laboratories are leading these advancements, creating products that allow for improved precision during embolization procedures. This increased technological capability will directly correlate with market growth as healthcare professionals increasingly adopt these new solutions. ### **Growth in the Geriatric Population** The aging population in the United States is a crucial factor affecting the growth of the US Transcatheter Embolization and Occlusion Devices Market Industry. According to the U.S. Census Bureau, the number of Americans aged 65 and older is projected to reach over 95 million by 2060, nearly double from 2015 figures. This demographic is more susceptible to conditions requiring transcatheter embolization, such as cardiovascular diseases and tumors. The growing geriatric population results in a higher demand for innovative and effective treatment options that transcatheter embolization devices can provide. With established companies like Johnson & Johnson and Cook Medical focusing on addressing the unique healthcare needs of older adults, the advancement and adoption of embolization technologies are set to rise sharply. ### **Increasing Investment in Healthcare Infrastructure** Increasing investment in healthcare infrastructure in the United States significantly bolsters the US Transcatheter Embolization and Occlusion Devices Market Industry. The American Hospital Association states that hospitals have invested over $45 billion in capital projects to expand services, including interventional radiology departments that utilize embolization techniques. With government initiatives and healthcare reforms aimed at improving accessibility and quality of care, hospitals and clinics are more likely to acquire advanced embolization technology. This influx of investment supports the development of advanced healthcare facilities equipped with cutting-edge devices, ultimately driving the growth of the market. Major players like Siemens Healthineers are collaborating with healthcare facilities to enhance their service capabilities, further influencing market dynamics. ## **US Transcatheter Embolization and Occlusion Devices Market Segment Insights** ### **Transcatheter Embolization and Occlusion Devices Market Device Type Insights** The US Transcatheter Embolization and Occlusion Devices Market demonstrates a robust framework that focuses on various device types, which are crucial for medical professionals engaged in vascular treatments and interventions. Among these, coils are widely recognized for their effectiveness in occluding blood vessels, particularly in procedures involving aneurysms and arteriovenous malformations. Their ease of use, along with a high success rate in achieving hemostasis, makes them essential tools in interventional radiology. Particles, on the other hand, are often applied in tumor embolization and achieving localized treatment effects. Their size and bio-compatibility enhance efficacy and minimize adverse reactions, catering to the growing demand for targeted therapies in the US healthcare landscape. Gels play a significant role in the embolization process, as they accord practitioners greater control over blood flow disruption, with their flow characteristics allowing more versatile applications in various anatomical contexts. Furthermore, liquid embolic agents have emerged as vital components, especially in complex cases where accessibility or conditions require intricate management. These agents can solidify in situ to create barriers against vascular flow, proving highly effective in more challenging clinical situations. Each device type not only contributes uniquely to the operational capabilities of healthcare providers but also influences current market trends driven by advancements in minimally invasive techniques, thus enhancing the overall efficacy of intervention strategies in the US Transcatheter Embolization and Occlusion Devices Market. Moreover, the consistent innovation in device materials and designs continues to foster growth opportunities in the field as healthcare systems increasingly adapt to the growing demand for precision medicine, highlighting the importance of understanding the complexities within the US Transcatheter Embolization and Occlusion Devices Market segmentation by device type. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Transcatheter Embolization and Occlusion Devices Market Application Insights** The US Transcatheter Embolization and Occlusion Devices Market focuses on various critical applications, highlighting its integral role in advanced medical procedures. Uterine Artery Embolization is significant due to its efficacy in treating fibroids, a common condition affecting many women in the U.S., making it a pivotal area. Tumor Embolization is equally notable, being crucial in cancer management, offering a minimally invasive alternative to traditional surgery for tumor reduction and management, which aligns with the growing trend towards less invasive interventions in the US healthcare system. Devascularization Procedures serve an essential purpose in various surgical settings, assisting in reducing blood flow to organs and tissues, and are often vital in preparing patients for surgeries by minimizing blood loss. Hemorrhage Control remains a priority in emergency medicine, providing effective solutions for trauma and surgical patients, thereby improving patient outcomes. The presence of a robust population seeking these procedures, along with continued advancements in medical technology, propels growth in these application areas within the US Transcatheter Embolization and Occlusion Devices Market, as healthcare providers and patients pursue effective, safe, and innovative treatment options. ### **Transcatheter Embolization and Occlusion Devices Market End User Insights** The End User segment of the US Transcatheter Embolization and Occlusion Devices Market plays a significant role in the overall dynamics of the industry. This segment primarily includes Hospitals, Ambulatory Surgical Centers, and Specialized Clinics, each contributing uniquely to the provision of care and treatment options. Hospitals are often the leading providers due to their extensive resources, advanced technology, and specialized medical personnel, making them crucial for complex procedures. Ambulatory Surgical Centers have gained traction due to their ability to offer outpatient procedures, enhancing patient convenience and reducing hospital stays, thus driving demand for transcatheter embolization devices. Specialized Clinics, focusing on niche areas of care, are vital for focused treatment and follow-up, ensuring high-quality outcomes for patients. Together, these end users create a framework that not only supports market growth through increased adoption and accessibility but also reflects the evolving healthcare landscape in the US, where patient-centric approaches and minimally invasive techniques are becoming predominant. The US government has also shown support for technological advancements and innovative care models, facilitating further advancements in this market sector. ### **Transcatheter Embolization and Occlusion Devices Market Technique Insights** The Technique segment within the US Transcatheter Embolization and Occlusion Devices Market plays a critical role in the overall framework of cardiovascular and interventional procedures. This segment primarily comprises Transcatheter Embolization and Surgical Embolization, both of which are essential for treating various conditions such as vascular malformations and tumors. Transcatheter Embolization has gained significant traction due to its minimally invasive nature, allowing for reduced recovery times and lower risk of complications. Meanwhile, Surgical Embolization continues to hold its place as a reliable method in more complex cases, where direct access to the affected area is needed. The growth in these techniques is driven by the increasing prevalence of conditions requiring embolization and the technological advancements that enhance procedural efficacy. Additionally, evolving healthcare policies and an increasing shift towards outpatient treatments in the US are contributing to the segment's prominence. As healthcare providers focus on improving patient outcomes and minimizing hospital stays, the Technique segment is expected to remain significant in the coming years, showcasing continued innovation and adoption. ## **US Transcatheter Embolization and Occlusion Devices Market Key Players and Competitive Insights** The US Transcatheter Embolization and Occlusion Devices Market is characterized by a competitive landscape with a plethora of players striving to gain larger market shares through innovative product offerings and strategic collaborations. This sector, which is essential for minimally invasive procedures involving the occlusion of blood vessels, is witnessing a surge in demand due to the rising incidence of various diseases requiring embolization. The market is also bolstered by technological advancements and an increasing focus on improving patient outcomes. The competitive insights reflect a mix of established companies and emerging players, each leveraging unique strengths to capture consumer interest. Key factors influencing competition include product efficacy, safety, regulatory approvals, and market accessibility, leading to an environment of dynamic interactions among competitors in the industry. Merit Medical Systems has established itself as a formidable player in the US Transcatheter Embolization and Occlusion Devices Market through an extensive portfolio of innovative medical devices designed to meet the diverse needs within this specific segment. The company's strengths lie in its commitment to research and development, helping it create advanced embolization solutions that cater to various clinical indications. Merit Medical Systems differentiates itself through its focus on quality and reliability, which enhances trust among healthcare professionals and patients alike. Additionally, by maintaining a robust distribution network and fostering relationships with hospitals and healthcare providers, the company has successfully positioned itself as a go-to resource for embolization and occlusion devices in the US. Terumo Corporation represents another key competitor in the US Transcatheter Embolization and Occlusion Devices Market, known for its wide range of high-quality medical products and innovative approaches in vascular intervention. Terumo's portfolio includes advanced embolization coils, vascular access systems, and balloon occlusion devices, which are vital for effective transcatheter procedures. The company is recognized for its strong presence and market penetration in the US, complemented by its commitment to continuous innovation and superior customer service. Terumo Corporation's strengths include its strategic emphasis on R&D, which has led to the introduction of cutting-edge technologies that enhance procedural efficiency and patient outcomes. Through various partnerships and potential mergers and acquisitions, Terumo remains poised to expand its influence and enhance its offerings in the embolization space, ensuring its competitive stance within the market. ### **Key Companies in the US Transcatheter Embolization and Occlusion Devices Market Include** ## **US Transcatheter Embolization and Occlusion Devices Market Industry Developments** Recent developments in the US Transcatheter Embolization and Occlusion Devices Market indicate a robust growth trajectory, attributed to increased procedural volumes and advancements in technology. Companies such as Merit Medical Systems, Terumo Corporation, and Medtronic are actively enhancing their product portfolios through innovative designs and improved materials. As of September 2023, Boston Scientific launched a new embolization device aimed at improving safety and efficacy in transcatheter procedures, further solidifying its market position. Abbott Laboratories also reported growth in its vascular portfolio, showing a strong presence in the embolization space. Current affairs highlight an ongoing focus on mergers and acquisitions, with Terumo Corporation acquiring a significant stake in a US-based medical device firm in July 2023 to bolster its embolization technologies. The market has seen the entrance of new players, influenced by favorable regulations and an increasing prevalence of conditions requiring embolization. Over the past few years, the US market has also experienced an uptick in demand for minimally invasive procedures, as patients increasingly prefer options that offer reduced recovery times. This trend is expected to continue, fostering further investments and innovations in the sector. ## **US Transcatheter Embolization and Occlusion Devices Market Segmentation Insights** ### **Transcatheter Embolization and Occlusion Devices Market Device Type Outlook** ### **Transcatheter Embolization and Occlusion Devices Market Application Outlook** ### **Transcatheter Embolization and Occlusion Devices Market End User Outlook** ### **Transcatheter Embolization and Occlusion Devices Market Technique Outlook** ## Market Drivers ### Advancements in Imaging Technologies The evolution of imaging technologies, such as MRI, CT scans, and fluoroscopy, plays a crucial role in enhancing the efficacy of transcatheter embolization procedures. These advancements allow for improved visualization of vascular structures, enabling more precise targeting during embolization. As a result, the transcatheter embolization-and-occlusion-devices market is likely to benefit from the integration of these technologies, which can lead to better patient outcomes and reduced procedural complications. The market for imaging technologies is projected to grow significantly, with estimates suggesting a CAGR of around 6% over the next few years. This synergy between imaging and embolization techniques may drive healthcare providers to adopt these devices more widely, thereby fostering market expansion. ### Increasing Prevalence of Chronic Diseases The rising incidence of chronic diseases such as cancer, cardiovascular disorders, and liver diseases is a primary driver for the transcatheter embolization-and-occlusion-devices market. As these conditions often require interventional procedures, the demand for effective embolization techniques is likely to increase. According to recent data, chronic diseases account for approximately 70% of all deaths in the US, highlighting the urgent need for innovative treatment options. This trend suggests that healthcare providers are increasingly adopting transcatheter embolization techniques to manage these conditions, thereby propelling market growth. Furthermore, the aging population, which is more susceptible to chronic ailments, is expected to further amplify the demand for these devices, indicating a robust market trajectory in the coming years. ### Expansion of Product Offerings by Key Players The transcatheter embolization-and-occlusion-devices market is witnessing an expansion of product offerings by key players, which is likely to enhance competition and drive innovation. Major manufacturers are investing in research and development to introduce advanced embolization devices that cater to a wider range of clinical applications. This includes the development of new materials, designs, and delivery systems that improve the efficacy and safety of embolization procedures. As companies strive to differentiate their products, the market is expected to see a surge in innovative solutions that meet the evolving needs of healthcare providers. This competitive landscape may lead to increased adoption of transcatheter embolization devices, further propelling market growth. ### Growing Investment in Healthcare Infrastructure Increased investment in healthcare infrastructure, particularly in interventional radiology departments, is a significant driver for the transcatheter embolization-and-occlusion-devices market. Hospitals and clinics are allocating more resources to upgrade their facilities and acquire advanced medical equipment, including embolization devices. This trend is supported by government initiatives aimed at improving healthcare access and quality. For instance, the US government has committed substantial funding to enhance healthcare services, which is likely to facilitate the adoption of innovative treatment modalities. As healthcare facilities become better equipped, the demand for transcatheter embolization devices is expected to rise, indicating a positive outlook for the market. ### Rising Awareness and Education Among Healthcare Professionals The increasing awareness and education regarding the benefits of transcatheter embolization techniques among healthcare professionals is driving the market forward. As more practitioners become knowledgeable about the advantages of these minimally invasive procedures, the adoption rate is likely to increase. Educational programs, workshops, and conferences focused on interventional radiology are becoming more prevalent, contributing to a better understanding of the applications and effectiveness of embolization devices. This heightened awareness may lead to a greater willingness among healthcare providers to recommend and utilize transcatheter embolization techniques, thereby positively impacting the market. The trend suggests a growing recognition of the importance of these devices in modern medical practice. ## Future Outlook The [Transcatheter Embolization and Occlusion Devices Market](https://www.marketresearchfuture.com/reports/transcatheter-embolization-and-occlusion-devices-market-7864) is projected to grow at a 7.78% CAGR from 2025 to 2035, driven by technological advancements and increasing procedural volumes. **New opportunities:** - Development of next-gen bioresorbable embolic agents Expansion into outpatient surgical centers Partnerships with telehealth platforms for remote monitoring By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships. ## Segment Insights ### By Type: Coils (Largest) vs. Particles (Fastest-Growing) In the US transcatheter embolization-and-occlusion-devices market, the distribution of market share across the segment types reveals that coils hold the largest share, primarily due to their widespread acceptance and efficiency in various embolization procedures. Particles, although currently having a smaller market share, are rapidly gaining traction owing to their expanding applications and improving clinical outcomes, driving increased adoption among healthcare providers. The growth trends within this segment are fueled by several factors, including advancements in material technology and the rising demand for less invasive procedures. As techniques become more refined, the market is witnessing a surge in demand for liquid embolic agents and particles, which are viewed as emerging alternatives to traditional methods. This transformative shift is indicative of the evolving landscape of interventional radiology and its impacts on clinical practices. Coils (Dominant) vs. Gels (Emerging) Coils are recognized as the dominant force in the US transcatheter embolization-and-occlusion-devices market due to their proven efficacy and versatility in treating various vascular conditions. They are often favored for their ability to conform to the anatomy of targeted vessels and provide reliable occlusion. On the other hand, gels are an emerging segment, showing promise for their ability to deliver controlled embolization with reduced complication rates. As techniques evolve and research expands, gels are being positioned as effective alternatives, particularly in cases where more traditional methods may not be appropriate. The market presence of these segments indicates a diversified approach to embolization strategies, catering to a wide spectrum of clinical needs and preferences. ### By Application: Uterine Artery Embolization (Largest) vs. Tumor Embolization (Fastest-Growing) The US transcatheter embolization-and-occlusion-devices market is characterized by a diverse range of applications. Uterine Artery Embolization holds the largest market share, benefiting from increasing demand for minimally invasive procedures targeting uterine fibroids. Following closely is Tumor Embolization, which has shown significant growth attributed to the rising incidence of cancers and advancements in targeted therapies. Devascularization Procedures and Hemorrhage Control, while important, occupy smaller shares in comparison amidst shifting healthcare trends. Growth trends in this segment reflect a broader shift towards less invasive, patient-centric treatments. Uterine Artery Embolization continues to dominate due to its effectiveness and reduced recovery times. On the other hand, Tumor Embolization is rapidly emerging, driven by technological advancements in embolic agents and significant research investments. Factors including aging demographics and increasing prevalence of chronic diseases are further propelling the market upward. Uterine Artery Embolization (Dominant) vs. Tumor Embolization (Emerging) Uterine Artery Embolization stands out as a dominant force in the US transcatheter embolization-and-occlusion-devices market, primarily due to its effectiveness in treating conditions such as fibroids while minimizing recovery times. This segment is well-established with a strong clinical backing and is often preferred by both patients and physicians. In contrast, Tumor Embolization is an emerging segment that is gaining traction, fueled by the rising incidence of tumors and cancer treatments. This segment is characterized by ongoing research and development activities, which are essential for introducing new products and techniques. The increasing recognition of Tumor Embolization as a viable treatment option is contributing to its rapid growth trajectory, making it an area of significant interest for healthcare professionals. ### By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the US transcatheter embolization-and-occlusion-devices market, hospitals represent the largest share of end users, largely due to their capability to provide comprehensive care and advanced treatments required for complex cases. This segment significantly dominates the market, benefiting from access to state-of-the-art technology and skilled professionals, which reinforces their position as the preferred choice for patients requiring embolization and occlusion procedures. Conversely, ambulatory surgical centers are emerging as the fastest-growing segment, driven by an increasing shift towards outpatient procedures and cost-effective treatments. Patients prefer these facilities for their efficiency and lower costs, prompting significant investments from healthcare providers to expand services and capabilities. The growth is further aided by technological advancements and increasing awareness of minimally invasive procedures, positioning ambulatory surgical centers as a key area of growth within the market. Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals command a dominant position in the US transcatheter embolization-and-occlusion-devices market, characterized by their extensive resources, advanced medical equipment, and multidisciplinary teams capable of managing complex patient cases. This robust infrastructure ensures high-quality care, making hospitals the preferred environment for intricate procedures. In contrast, ambulatory surgical centers are emerging as a vital player by offering specialized services with a focus on outpatient care. Their flexibility and efficiency attract patients seeking shorter recovery times and reduced hospital stays. While hospitals focus on comprehensive treatment, ambulatory centers are leveraging technological advancements and patient-centric approaches, demonstrating a strong growth trajectory in the evolving landscape of healthcare. ### By Technique: Transcatheter Embolization (Largest) vs. Surgical Embolization (Fastest-Growing) The US transcatheter embolization-and-occlusion-devices market demonstrates a clear market share distribution where Transcatheter Embolization holds the largest segment. It has gained significant traction due to advancements in technology and increasing acceptance among healthcare providers. In contrast, Surgical Embolization, while smaller in market share, is rapidly gaining momentum owing to its effectiveness in specific clinical indications and new surgical techniques that are being adopted. Growth trends in this segment are influenced by various factors including an increasing prevalence of vascular diseases and the continuous development of minimally invasive procedures. The focus on patient safety and recovery times has further propelled the demand for transcatheter embolization techniques. Moreover, a growing number of clinical studies supporting the efficacy of these techniques continue to drive their acceptance in the medical community. Technique: Transcatheter Embolization (Dominant) vs. Surgical Embolization (Emerging) Transcatheter Embolization is recognized as the dominant technique in the US transcatheter embolization-and-occlusion-devices market, primarily due to its efficacy in treating complex conditions and less invasive nature. This technique allows for targeted treatment, minimizing the risk associated with larger surgical procedures. Conversely, Surgical Embolization is considered an emerging technique that, while effective, is not as widely adopted as Transcatheter Embolization. Its growth can be attributed to recent innovations in surgical methods and the incorporation of advanced technologies, making it an appealing option for certain patient demographics. Both techniques continue to evolve, but Transcatheter Embolization leads the market, driven by its established reliability and safety records. ## Competitive Benchmarking The transcatheter embolization-and-occlusion-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for minimally invasive procedures. Key players such as Medtronic (US), Boston Scientific (US), and Abbott Laboratories (US) are at the forefront, focusing on innovation and strategic partnerships to enhance their market presence. Medtronic (US) emphasizes its commitment to developing cutting-edge embolization devices, while Boston Scientific (US) leverages its extensive product portfolio to cater to diverse clinical needs. Abbott Laboratories (US) appears to be concentrating on expanding its market share through targeted acquisitions and collaborations, thereby shaping a competitive environment that prioritizes innovation and comprehensive solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure is moderately fragmented, with several players vying for dominance. However, the collective influence of major companies like Stryker Corporation (US) and Johnson & Johnson (US) is notable, as they continue to invest in research and development to maintain competitive advantages. This competitive structure fosters an environment where innovation is paramount, and companies are compelled to differentiate themselves through advanced technologies and superior product offerings. In October 2025, Medtronic (US) announced the launch of its latest embolization device, which integrates AI technology to improve procedural outcomes. This strategic move not only underscores Medtronic's commitment to innovation but also positions the company to capitalize on the growing trend of digitalization in healthcare. The incorporation of AI is likely to enhance the precision and effectiveness of embolization procedures, thereby attracting a broader customer base. In September 2025, Boston Scientific (US) entered into a partnership with a leading healthcare technology firm to develop next-generation embolization solutions. This collaboration is indicative of Boston Scientific's strategy to leverage external expertise and accelerate product development. By aligning with technology innovators, the company aims to enhance its product offerings and maintain a competitive edge in a rapidly evolving market. In August 2025, Abbott Laboratories (US) completed the acquisition of a smaller firm specializing in embolization technologies. This acquisition is strategically significant as it allows Abbott to expand its product portfolio and enhance its capabilities in the embolization space. The integration of new technologies and expertise from the acquired firm is expected to bolster Abbott's position in the market, enabling it to offer more comprehensive solutions to healthcare providers. As of November 2025, current trends in the transcatheter embolization-and-occlusion-devices market include a pronounced focus on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This shift suggests that companies that prioritize R&D and strategic partnerships will be better positioned to thrive in the future. ## Recent News & Developments Recent developments in the US Transcatheter Embolization and Occlusion Devices Market indicate a robust growth trajectory, attributed to increased procedural volumes and advancements in technology. Companies such as Merit Medical Systems, Terumo Corporation, and Medtronic are actively enhancing their product portfolios through innovative designs and improved materials. As of September 2023, Boston Scientific launched a new embolization device aimed at improving safety and efficacy in transcatheter procedures, further solidifying its market position. Abbott Laboratories also reported growth in its vascular portfolio, showing a strong presence in the embolization space. Current affairs highlight an ongoing focus on mergers and acquisitions, with Terumo Corporation acquiring a significant stake in a US-based medical device firm in July 2023 to bolster its embolization technologies. The market has seen the entrance of new players, influenced by favorable regulations and an increasing prevalence of conditions requiring embolization. Over the past few years, the US market has also experienced an uptick in demand for minimally invasive procedures, as patients increasingly prefer options that offer reduced recovery times. This trend is expected to continue, fostering further investments and innovations in the sector. ## Report Scope | MARKET SIZE 2024 | 604.7(USD Million) | | --- | --- | | MARKET SIZE 2025 | 651.75(USD Million) | | MARKET SIZE 2035 | 1378.67(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.78% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Medtronic (US), Boston Scientific (US), Terumo Corporation (JP), Abbott Laboratories (US), Johnson & Johnson (US), Cook Medical (US), B. Braun Melsungen AG (DE), Stryker Corporation (US), Cardinal Health (US) | | Segments Covered | Type, Application, End User, Technique | | Key Market Opportunities | Advancements in minimally invasive techniques enhance growth potential in the transcatheter embolization-and-occlusion-devices market. | | Key Market Dynamics | Technological advancements and regulatory changes drive growth in the transcatheter embolization-and-occlusion-devices market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current market valuation of the US transcatheter embolization-and-occlusion-devices market?** A: The market valuation was $604.7 Million in 2024. **Q: What is the projected market size for the US transcatheter embolization-and-occlusion-devices market by 2035?** A: The projected market size is $1378.67 Million by 2035. **Q: What is the expected CAGR for the US transcatheter embolization-and-occlusion-devices market during the forecast period 2025 - 2035?** A: The expected CAGR is 7.78% during the forecast period 2025 - 2035. **Q: Which companies are the key players in the US transcatheter embolization-and-occlusion-devices market?** A: Key players include Medtronic, Boston Scientific, Terumo Corporation, Abbott Laboratories, Johnson & Johnson, Cook Medical, B. Braun Melsungen AG, Stryker Corporation, and Cardinal Health. **Q: What are the main types of devices in the US transcatheter embolization-and-occlusion-devices market?** A: Main types include Coils, Particles, Gels, and Liquid Embolic Agents. **Q: What was the market valuation for Liquid Embolic Agents in 2024?** A: The market valuation for Liquid Embolic Agents was $254.7 Million in 2024. **Q: What applications are driving the US transcatheter embolization-and-occlusion-devices market?** A: Key applications include Uterine Artery Embolization, Tumor Embolization, Devascularization Procedures, and Hemorrhage Control. **Q: What was the market valuation for Tumor Embolization in 2024?** A: The market valuation for Tumor Embolization was $181.41 Million in 2024. **Q: Which end users are primarily utilizing transcatheter embolization-and-occlusion-devices?** A: Primary end users include Hospitals, Ambulatory Surgical Centers, and Specialized Clinics. **Q: What was the market valuation for Hospitals in 2024?** A: The market valuation for Hospitals was $242.1 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-transcatheter-embolization-and-occlusion-devices-market-17633*